Epidemiology of primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV) in the European Union (EU)

被引：0
|
作者：
Mehta, J. [1 ]
Le-Ruyet, O. [2 ]
Fryzek, J. [3 ]
Iqbal, S. U. [1 ]
Mesa, R. [4 ]
机构：
[1] Sanofi Aventis, Evidence & Value Dev, Cambridge, MA USA
[2] Sanofi Aventis, Evidence & Value Dev, Chilly Mazarin, France
[3] Epidstat Inst, Ann Arbor, MI USA
[4] Mayo Clin, Div Hematol & Med Oncol, Scottsdale, AZ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1489
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [1] Epidemiology of Myelofibrosis (MF), Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the European Union (EU)
    Moulard, Odile
    Mehta, Jyotsna
    Olivares, Robert
    Iqbal, Usman
    Mesa, Ruben A.
    BLOOD, 2012, 120 (21)
  • [2] Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
    Moulard, Odile
    Mehta, Jyotsna
    Fryzek, Jon
    Olivares, Robert
    Iqbal, Usman
    Mesa, Ruben A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (04) : 289 - 297
  • [3] A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, John
    Sandy, Lonette
    Lu, Min
    Yoon, James
    Petersen, Bruce
    Zhang, David
    Ye, Fei
    Newsom, Carrie
    Najfeld, Vesna
    Hochman, Tsivia
    Goldberg, Judith D.
    Hoffman, Ronald
    LEUKEMIA RESEARCH, 2017, 53 : 13 - 19
  • [4] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [5] A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi), in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), and Post Polycythemia Vera (PV) Myelofibrosis
    DeAngelo, Daniel J.
    Tefferi, Ayalew
    Fiskus, Warren
    Mesa, Ruben A.
    Paley, Carole S.
    Wadleigh, Martha
    Snyder, David S.
    Begna, Kebede
    Ondovik, Michael S.
    Rine, Jessica
    Bhalla, Kapil N.
    BLOOD, 2010, 116 (21) : 276 - 277
  • [6] A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis
    DeAngelo, D. J.
    Tefferi, A.
    Mesa, R. A.
    Paley, C. S.
    Wadleigh, M.
    Snyder, D.
    Ondovik, M. S.
    Rine, J.
    Bhalla, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
    Silver, Richard T.
    Kiladjian, Jean-Jacques
    Hasselbalch, Hans Carl
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (01) : 49 - 58
  • [8] MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia
    Anil Tombak
    Ozlem Izci Ay
    Mehmet Emin Erdal
    Mehmet Ali Sungur
    Mehmet Ali Ucar
    Aydan Akdeniz
    Eyup Naci Tiftik
    Indian Journal of Hematology and Blood Transfusion, 2015, 31 : 416 - 425
  • [9] MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia
    Tombak, Anil
    Ay, Ozlem Izci
    Erdal, Mehmet Emin
    Sungur, Mehmet Ali
    Ucar, Mehmet Ali
    Akdeniz, Aydan
    Tiftik, Eyup Naci
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2015, 31 (04) : 416 - 425
  • [10] A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H. M.
    Pardanani, A.
    Thomas, D. A.
    Cortes, J. E.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Tefferi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345